General description
一种脂质类激酶的泛素I类PI3K（磷脂酰肌醇3-激酶）抑制剂，作用于p110α、p110β、p110δ和p110γ，IC50分别为52nM、166nM、116nM和262nM。
Buparlisib is an orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. PI3K inhibitor BKM120 specifically inhibits class I PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway。
Buparlisib是泛I类磷脂酰肌醇3-激酶（PI3K）家族的具有潜在抗肿瘤活性的口服生物利用型特定口服抑制剂。 PI3K抑制剂BKM120以ATP竞争的方式特异性抑制PI3K / AKT激酶（或蛋白激酶B）信号传导途径中的I类PIK3，从而抑制次级信使磷脂酰肌醇-3,4,5-三磷酸的产生以及其活化。 PI3K信号通路。
安全信息
![图片 辅酶A水合物，Coenzyme A (free acid) [CoA]；Avanti Polar Lipids, powder](https://www.bszh.cn/images/thumbs/0004775_acoenzyme-a-free-acid-coaavanti-polar-lipids-powder_32.png "显示明细 辅酶A水合物，Coenzyme A (free acid) [CoA]；Avanti Polar Lipids, powder")
![图片 蛋白胨来源于酪蛋白 [蛋白质水解产物]，Protein Hydrolysate N-Z-Amine® AS；suitable for microbiology](https://www.bszh.cn/images/thumbs/default-image_32.png "显示明细 蛋白胨来源于酪蛋白 [蛋白质水解产物]，Protein Hydrolysate N-Z-Amine® AS；suitable for microbiology")
![图片 他莫昔芬 [泰莫西芬]，Tamoxifen；powder, Suitable for cell culture, ≥99%](https://www.bszh.cn/images/thumbs/0012620_-tamoxifenpowder-suitable-for-cell-culture-99_32.png "显示明细 他莫昔芬 [泰莫西芬]，Tamoxifen；powder, Suitable for cell culture, ≥99%")
京公网安备 11010902000808号 | 京ICP备11047009号-1